ENTITY

Halozyme Therapeutics (HALO US)

28
Analysis
Health Care • United States
Halozyme Therapeutics, Inc. is a biopharmaceutical company developing products for the diabetes, cancer, dermatology and drug delivery markets. The Company's platform technology is based on recombinant human hyaluronidase plus additional enzymes. Halozyme applies its technology to its proprietary programs and to partnerships with pharmaceutical companies.
more
bullish•Rigetti Computing
•26 Nov 2025 06:06

Back to Near-Term Bullish on SPX and Nasdaq 100; Supports Held at SPX 6480-6520 and QQQ $580-583

Back to Near-Term Bullish on $SPX and Nasdaq 100 $NDX; Crucial Supports Held at 6480-6520 on SPX and $580-$583 on $QQQ, we are near-term bullish as...

Logo
377 Views
Share
•21 May 2025 19:39•Issuer-paid

Biopharma Week in Review MFN Fears Overdone but Medicare Negotiation Changes Reapplied Pressure

President Trump’s MFN executive order lacked a clear plan to lower drug prices, with any immediate moves likely facing legal challenges.

Logo
299 Views
Share
•05 Jan 2025 07:30

APAC Healthcare Weekly (Jan 5)- Beigene, Innovent Biologics, CSPC Pharma, Hutchmed, Yuhan, Lupin

APAC healthcare companies got approvals for new products as well as clinical trials. The companies continued with acquisitions and collaborations...

Logo
596 Views
Share
bullish•Diamondback Energy
•26 Jun 2024 08:10

Rotation Is the Lifeblood of a Bull Market; Still Bullish; Supports at SPX 5370-5380, QQQ $468-469

Rotation is the Lifeblood of a Bull Market; Bullish Outlook Intact; Expecting Short-term Support at $SPX 5370-5380 and $QQQ $468-469 (20-day MAs...

Logo
416 Views
Share
•11 Jul 2022 09:19•Syndicated

Weekly Stock Bullfinder - Week of 7/11

The war in Ukraine has thrown Europe into a full blown energy crisis that has resulted in a cost of living crisis for many EU countries as food and...

Share
x